bioRxiv · 10.1101/2020.11.02.328013
Correction of a Factor VIII genomic inversion with designer-recombinases
Abstract
Despite advances in nuclease-based genome editing technologies, correcting human disease-causing genomic inversions remains a challenge. Here, we describe the potential use of a recombinase-based system to correct a 140 kb genomic inversion of the F8 gene, which is frequently found in patients diagnosed with severe Hemophilia A. Employing substrate-linked directed molecular evolution, we developed a fused heterodimeric recombinase system (RecF8) achieving 30% inversion of the target sequence in human tissue culture cells. Transient RecF8 treatment of endothelial cells, differentiated from patient derived induced pluripotent stem cells (iPSCs) of a hemophilic donor, resulted in prominent correction of the inversion and restored Factor VIII mRNA expression. Our data suggests that designer-recombinases may represent efficient and specific means towards treatment of monogenic diseases caused by large gene inversions.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Lansing, F., Mukhametzyanova, L., Rojo-Romanos, T., Iwasawa, K., Kimura, M., Paszkowski-Rogacz, M., Karpinski, J., Grass, T., Sonntag, J., Schneider, P. M., Günes, C., Hoersten, J., Schmitt, L. T., Rodriguez-Muela, N., Knöfler, R., Takebe, T., Buchholz, F.. 2020-11-02. Correction of a Factor VIII genomic inversion with designer-recombinases. https://doi.org/10.1101/2020.11.02.328013
Cite the original work for its findings. Save a collection to share your selection of sources.